Rising uncertainty pushed by US tariffs and proposed “most-favoured nation” pricing is prompting pharmaceutical firms to delay funding and product launches in Europe.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
